Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

This Microcap Pharma Stock Almost Doubled Today - Read Why

  • UnitedHealthcare has added Kala Pharmaceuticals Inc's (NASDAQ:KALA) Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies effective March 2022
  • Eysuvis now has coverage for approximately 118 million lives or 70% of all commercial lives.
  • Kala also announced that Cigna Medicare had added Eysuvis as a preferred brand effective February 2022, adding 1.9 million Medicare lives. 
  • Eysuvis has Medicare preferred coverage for select plans with Express Scripts, Prime Therapeutics, and Cigna Inc (NASDAQ:CI). 
  • Related: Kala Pharma Acquires Ocular Surface Disease-Focused Company.
  • Total Eysuvis Medicare coverage is now approximately 7.1 million lives, or 15% of all Medicare lives.
  • Eysuvis became commercially available in January 2021 as the first and only FDA-approved medicine for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease.
  • Price Action: KALA shares gained 88.50% to close at $1.15 on Tuesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.